Therapeutics News and Research

RSS

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

New research suggests that Alzheimer's gene may begin to affect brains in childhood

People who carry a high-risk gene for Alzheimer's disease show changes in their brains beginning in childhood, decades before the illness appears, new research from the Centre for Addiction and Mental Health suggests.

3 Dec 2013

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra, Inc., a developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds from an upsized and final closing of its Series A financing round. The company also announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, which follows the recent appointment of Brian Pereira, M.D. as President and Chief Executive Officer of Visterra this past summer.

2 Dec 2013

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Cell Therapeutics, Inc. today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOX (arsenic trioxide).

2 Dec 2013

World-class Krembil Discovery Tower now opens in Canada

The Honourable Dr. K. Kellie Leitch, Minister of Labour and Minister of Status of Women congratulated Toronto Western Hospital today on the opening of the Krembil Discovery Tower, a facility dedicated to research excellence, training the next generation of medical professionals and improving health care for patients across Canada.

2 Dec 2013

Pivotal Therapeutics reports financial results for Q3 2013

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.

30 Nov 2013

Osiris: CMS releases proposed ruling for reimbursement of skin substitutes in hospital outpatient setting

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care, announced today that, on November 27, 2013, the Centers for Medicare and Medicaid Services released their proposed ruling for the reimbursement of skin substitutes in the hospital outpatient setting. CMS decided to package the reimbursement for products used in advanced wound care with the related surgical procedure into a two-tier system.

30 Nov 2013

Elevated cholesterol is associated with breast cancer risk

A byproduct of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, researchers at the Duke Cancer Institute report.

29 Nov 2013

NIBIB-funded researchers explore better treatment for brain aneurysms

Thirty thousand Americans suffer severe neurological damage or death from brain aneurysms each year and the existing treatments eventually fail in nearly half of patients. Currently, these "bubbles" in the blood vessel are either clamped off, which requires invasive brain surgery, or filled with platinum coils to induce clotting in the aneurysm. Both treatments, although somewhat effective, can have subsequent problems, including inflammation, incomplete healing, and the development of secondary aneurysms adjacent to the initial site. These complications result in approximately 40 percent of patients needing additional treatment to attempt to re-repair the aneurysm.

28 Nov 2013

Protecting or boosting neurotrophins may slow progression of Huntington's disease

A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.

27 Nov 2013

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-GSK3Rx and earned a $3 million milestone payment from GlaxoSmithKline.

27 Nov 2013

Breakthrough discovery could lead to development of future therapeutics for prostate cancer

Drs. Andrew Goldstein, Owen Witte, and Tanya Stoyanova and their colleagues from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published online ahead of print in the Proceedings of the National Academy of Sciences.

27 Nov 2013

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

A team of researchers at Cold Spring Harbor Laboratory (CSHL) has identified a leukemia-specific stretch of DNA called an enhancer element that enables cancerous blood cells to proliferate in Acute Myeloid Leukemia (AML), a devastating cancer that is incurable in 70% of patients.

27 Nov 2013

EU-funded project develops new type of vaccine to tackle HIV virus infection

AIDS research has attempted many strategies to tackle the HIV virus infection. Now, a new type of vaccine developed within an EU-funded project, called EuroNeut-41, is based on one of the envelope proteins of the HIV virus, called the gp41 protein. What makes it interesting it that it is directly responsible for the fusion of the HIV virus into human cells. By integrating the gp41 protein into the vaccine, researchers try to trigger the production of antibodies that would block the entrance of HIV into human cells

27 Nov 2013

Principal investigators at Nationwide Children's Hospital elected as AAAS Fellows

Brian K. Kaspar, PhD, and Veronica J. Vieland, PhD, principal investigators in The Research Institute at Nationwide Children's Hospital, have been named Fellows of the American Association for the Advancement of Science (AAAS).

26 Nov 2013

Researchers identify new mechanism that causes neurodegeneration

As we age, our body rhythms lose time before they finally stop. Breaking the body clock by genetically disrupting a core clock gene, Bmal1, in mice has long been known to accelerate aging , causing arthritis, hair loss, cataracts, and premature death.

26 Nov 2013

Seed grants support cancer diagnosis and treatment, vascular health research

Five teams of scientists earned research seed grants awarded this year by the John S. Dunn Foundation. The awards support new collaborations by researchers at Rice University's BioScience Research Collaborative (BRC) and their partners at other institutional members of the Gulf Coast Consortia (GCC).

26 Nov 2013

Therapeutics News and Research

Research findings pave new ways to treat gastrointestinal disorders

New research suggests that Alzheimer's gene may begin to affect brains in childhood

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

World-class Krembil Discovery Tower now opens in Canada

Pivotal Therapeutics reports financial results for Q3 2013

Osiris: CMS releases proposed ruling for reimbursement of skin substitutes in hospital outpatient setting

Elevated cholesterol is associated with breast cancer risk

NIBIB-funded researchers explore better treatment for brain aneurysms

Protecting or boosting neurotrophins may slow progression of Huntington's disease

Isis Pharmaceuticals commences Phase 1 study of ISIS-GSK3Rx for treatment of common viral infection

Breakthrough discovery could lead to development of future therapeutics for prostate cancer

CSHL identifies specific stretch of DNA that helps cancerous blood cells to proliferate in AML

EU-funded project develops new type of vaccine to tackle HIV virus infection

Principal investigators at Nationwide Children's Hospital elected as AAAS Fellows

Researchers identify new mechanism that causes neurodegeneration

Seed grants support cancer diagnosis and treatment, vascular health research

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News